Michel Fabbro - Concepedia

Author

Michel Fabbro

Institut de Recherche en Cancérologie de Montpellier ORCID

Also Known As

Coraline Dubot, J.-M. Extra, M Fabbro, M. FABBRO, M. Fabbro, MICHEL FABBRO, Maeva Chauvin, Michel Fabbro, Nadine Dohollou, Nina Deliu

423

Publications

11.5K

Citations

H-Index

Concepts

All Affiliations

Institut de Recherche en Cancérologie de Montpellier Institut Gustave Roussy Centre Léon Bérard Sorbonne Université Inserm

About

Michel Fabbro is an author at Institut de Recherche en Cancérologie de Montpellier specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	63	4.4K
2	Health Sciences	12	14	462
3	Cell Biology	4	4	199
4	Public Health	3	3	168
5	Nursing	1	1	13

Michel Fabbro

105

Publications

10.1K

Citations

H-Index

Page 1

	Year	Citations
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, New England Journal of Medicine	2016	2.4K
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Michael Weller, Nicholas Butowski, David Tran, The Lancet Oncology Egfrviii-expressing GlioblastomaNeuro-oncologyAct IvGliomaInternational Phase 3	2017	1.1K
Lomustine and Bevacizumab in Progressive Glioblastoma Wolfgang Wick, Thierry Gorlia, Martin Bendszus, New England Journal of Medicine	2017	949
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial Bradley J. Monk, Andrés Poveda, Ignace Vergote, The Lancet Oncology OncologyPlacebo-controlled Phase 3Metronomic TherapyClinical TrialsGynecology	2014	304
Management and outcome of primary CNS lymphoma in the modern era Caroline Houillier, Carole Soussain, Hervé Ghesquières, Neurology	2020	229
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network Sophie Langner-Lemercier, Caroline Houillier, Carole Soussain, Neuro-Oncology	2016	189
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004 Luc Bauchet, Hélène Mathieu‐Daudé, Pascale Fabbro-Péray, Neuro-Oncology	2010	177
Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer Catherine Alix‐Panabières, Jean-Pierre Vendrell, Monique Slijper, Breast Cancer Research	2009	176
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, The Lancet OncologyCervical CancerMetronomic TherapyPathologyRecurrent Cervical Cancer	2023	175
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer Anthony Gonçalvès, Michel Fabbro, C. Lhommé, Gynecologic Oncology Cervical Cancer ManagementMetastatic Cervical CancerCervical CancerPhase Ii TrialMedicine	2007	137

Page 1